Author information:
(1)From the Departments of Pediatrics (S.L.M., S.A.G.) and Pathology and 
Laboratory Medicine (C.H.J., B.L.L.), Perelman School of Medicine, and Abramson 
Cancer Center (C.H.J., B.L.L.), University of Pennsylvania, and the Division of 
Oncology, Center for Childhood Cancer Research and Cancer Immunotherapy Program, 
Children's Hospital of Philadelphia (S.L.M., S.A.G.) - all in Philadelphia; the 
Department of Pediatrics and Harold C. Simmons Comprehensive Cancer Center, 
University of Texas Southwestern Medical Center, and the Pauline Allen Gill 
Center for Cancer and Blood Disorders, Children's Health, Dallas (T.W.L.); the 
Department of Pediatric Hematology and Oncology, Oslo University Hospital, Oslo 
(J.B.); the Department of Pediatric Hematology and Oncology, Hospital Sant Joan 
de Deu Barcelona, Barcelona (S.R.); the Department of Pediatrics and Internal 
Medicine, University of Utah, Salt Lake City (M.B.); the Department of 
Pediatrics, Faculty of Medicine, University of Montreal, and the Hematology 
Oncology Division and Charles-Bruneau Cancer Center, Centre Hospitalier 
Universitaire Sainte-Justine Research Center, Montreal (H.B.), and the Division 
of Haematology/Oncology/Bone Marrow Transplantation, Hospital for Sick Children, 
Toronto (J.K.) - all in Canada; the Division of Stem Cell Transplantation and 
Immunology, Hospital for Children and Adolescents, University Hospital 
Frankfurt, Frankfurt, Germany (P.B.); the Division of Pediatric Blood and Marrow 
Transplant, University of Minnesota, Minneapolis (M.R.V., H.E.S.); Children's 
Mercy Hospital and Clinics, Kansas City, MO (G.D.M.); Aflac Cancer and Blood 
Disorders Center, Emory University, Atlanta (M.Q.); the Department of Pediatric 
Hematology-Oncology and Stem Cell Transplantation, Ghent University Hospital, 
and the Cancer Research Institute Ghent (CRIG), Ghent, Belgium (B.D.M.); the 
Department of Pediatrics, Graduate School of Medicine Kyoto University, Kyoto, 
Japan (H.H.); the Department of Pediatrics, Stanford University School of 
Medicine, Stanford (K. Schlis, K.L.D.), and the Division of Hematology, 
Oncology, Blood and Marrow Transplant, Children's Hospital Los Angeles, USC Keck 
School of Medicine, Los Angeles (M.A.P.) - all in California; the Division of 
Pediatric Blood and Marrow Transplant, Duke University Medical Center, Durham, 
NC (P.L.M.); Oregon Health and Science University, Portland (E.R.N.); C.S. Mott 
Children's Hospital, Ann Arbor, MI (G.A.Y.); the Stem Cell Transplantation Unit, 
St. Anna Children's Hospital, Vienna (C.P.); University Hospital Robert Debré 
and University Paris Diderot (A. Baruchel), and Saint-Louis Hospital and 
University Paris Diderot (N.B.), Paris; the Royal Children's Hospital, 
Melbourne, VIC, Australia (F.M.); Clinica Pediatrica Universita degli Studi di 
Milano Bicocca, Monza, Italy (A. Balduzzi); and Novartis Pharmaceuticals (P.W., 
T.T., M.L., Y.Z., K. Sen, D.L.) and Novartis Institutes for Biomedical Research 
(K.T.M.) - both in East Hanover, NJ.